Molecular Partners Expands Clinical Collaboration With Orano Med to Add 6 Targeted Alpha Radio-Therapies for Cancer

MT Newswires Live

01-13

Molecular Partners AG0.00%盘后

Molecular Partners AG (MOLN) expanded its strategic collaboration with Orano Med to include the development of an additional six targeted alpha radio-therapies for cancer, the companies said Sunday.

The companies entered into an initial agreement in January 2024 to co-develop four programs.

Under the expanded collaboration, Molecular Partners will lead the development of the six additional programs, with an option for Orano Med to move for the co-development of two of the six programs.

Financial terms were not disclosed.

The company said it expects the deal to have no immediate impact on its fiscal 2025 financial outlook.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

no data

没有相关数据

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503792353"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503792353\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503792353?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-13 18:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503792353","market":"fut","top_or_hot":-1,"title":"Molecular Partners Expands Clinical Collaboration With Orano Med to Add 6 Targeted Alpha Radio-Therapies for Cancer","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MLLCF\">Molecular Partners AG</a> (MOLN) expanded its strategic collaboration with Orano Med to include the development of an additional six targeted alpha radio-therapies for cancer, the companies said Sunday.</p><p>The companies entered into an initial agreement in January 2024 to co-develop four programs.</p><p>Under the expanded collaboration, Molecular Partners will lead the development of the six additional programs, with an option for Orano Med to move for the co-development of two of the six programs.</p><p>Financial terms were not disclosed.</p><p>The company said it expects the deal to have no immediate impact on its fiscal 2025 financial outlook.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Molecular Partners Expands Clinical Collaboration With Orano Med to Add 6 Targeted Alpha Radio-Therapies for Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMolecular Partners Expands Clinical Collaboration With Orano Med to Add 6 Targeted Alpha Radio-Therapies for Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-13 18:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MLLCF\">Molecular Partners AG</a> (MOLN) expanded its strategic collaboration with Orano Med to include the development of an additional six targeted alpha radio-therapies for cancer, the companies said Sunday.</p><p>The companies entered into an initial agreement in January 2024 to co-develop four programs.</p><p>Under the expanded collaboration, Molecular Partners will lead the development of the six additional programs, with an option for Orano Med to move for the co-development of two of the six programs.</p><p>Financial terms were not disclosed.</p><p>The company said it expects the deal to have no immediate impact on its fiscal 2025 financial outlook.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503792353","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503792353","pubTimestamp":1736763992,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Molecular Partners AG  expanded its strategic collaboration with Orano Med to include the development of an additional six targeted alpha radio-therapies for cancer, the companies said Sunday.The companies entered into an initial agreement in January 2024 to co-develop four programs.Under the expanded collaboration, Molecular Partners will lead the development of the six additional programs, with an option for Orano Med to move for the co-development of two of the six programs.Financial terms were not disclosed.The company said it expects the deal to have no immediate impact on its fiscal 2025 financial outlook.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Molecular Partners扩大与Orano Med的临床合作，增加6种癌症靶向α放射疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MOLN":0.9},"content_text":"Molecular Partners AG (MOLN) expanded its strategic collaboration with Orano Med to include the development of an additional six targeted alpha radio-therapies for cancer, the companies said Sunday.The companies entered into an initial agreement in January 2024 to co-develop four programs.Under the expanded collaboration, Molecular Partners will lead the development of the six additional programs, with an option for Orano Med to move for the co-development of two of the six programs.Financial terms were not disclosed.The company said it expects the deal to have no immediate impact on its fiscal 2025 financial outlook.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1}}}

如果下载按钮点击无跳转，请点击右上角菜单选择 “在浏览器打开”

立即咨询
下载APP
扫码下载APP